BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 12384800)

  • 1. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
    Ashida S; Nishimori I; Tanimura M; Onishi S; Shuin T
    J Cancer Res Clin Oncol; 2002 Oct; 128(10):561-8. PubMed ID: 12384800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes.
    Ivanov SV; Kuzmin I; Wei MH; Pack S; Geil L; Johnson BE; Stanbridge EJ; Lerman MI
    Proc Natl Acad Sci U S A; 1998 Oct; 95(21):12596-601. PubMed ID: 9770531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa.
    Kivela AJ; Parkkila S; Saarnio J; Karttunen TJ; Kivela J; Parkkila AK; Bartosova M; Mucha V; Novak M; Waheed A; Sly WS; Rajaniemi H; Pastorekova S; Pastorek J
    World J Gastroenterol; 2005 May; 11(17):2616-25. PubMed ID: 15849821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
    Jensen RL; Gillespie D; House P; Layfield L; Shelton C
    J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines.
    Jakubicková L; Biesová Z; Pastoreková S; Kettmann R; Pastorek J
    Int J Oncol; 2005 Apr; 26(4):1121-7. PubMed ID: 15754010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
    Koochekpour S; Jeffers M; Wang PH; Gong C; Taylor GA; Roessler LM; Stearman R; Vasselli JR; Stetler-Stevenson WG; Kaelin WG; Linehan WM; Klausner RD; Gnarra JR; Vande Woude GF
    Mol Cell Biol; 1999 Sep; 19(9):5902-12. PubMed ID: 10454537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
    Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
    Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
    Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
    Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The VHL-dependent regulation of microRNAs in renal cancer.
    Neal CS; Michael MZ; Rawlings LH; Van der Hoek MB; Gleadle JM
    BMC Med; 2010 Oct; 8():64. PubMed ID: 20964835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
    Igarashi H; Esumi M; Ishida H; Okada K
    Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma.
    Perera AD; Kleymenova EV; Walker CL
    Clin Cancer Res; 2000 Apr; 6(4):1518-23. PubMed ID: 10778984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma.
    Hamano K; Esumi M; Igarashi H; Chino K; Mochida J; ISHIDA And H; Okada K
    J Urol; 2002 Feb; 167(2 Pt 1):713-7. PubMed ID: 11792959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.
    Mukhopadhyay D; Knebelmann B; Cohen HT; Ananth S; Sukhatme VP
    Mol Cell Biol; 1997 Sep; 17(9):5629-39. PubMed ID: 9271438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of MN/CA IX antigen in carcinogenesis and metastasis of renal cell carcinoma].
    Nakagawa Y; Uemura H; Shimizu K; Cho M; Yoshikawa M; Hirao Y; Yoshikawa K
    Hinyokika Kiyo; 2001 Nov; 47(11):809-14. PubMed ID: 11771176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.